Clinical Trial Update: A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described

View source ↗

Summary

An observational study of non-metastatic castration-resistant prostate cancer patients who had already decided to be treated with darolutamide before enrollment…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-metastatic Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Darolutamide (darolutamide)

Snippet

Sponsor: Bayer | Conditions: Prostate Cancer | Status: ACTIVE_NOT_RECRUITING